Tissue plasminogen activator (tPA) thrombolysis continues to be the gold standard therapy
for ischemic stroke. Due to the time-limited treatment window, within 4.5 h of stroke onset …

Tissue plasminogen activator (tPA) thrombolysis remains the gold standard treatment for
ischemic stroke. A time-constrained therapeutic window, with the drug to be given within 4.5 …

To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard
treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset …

Tissue plasminogen activator (tPA) is the only therapeutic agent approved to treat patients
with acute ischemic stroke. The clinical benefits of tPA manifest when the agent is …

Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective
treatment for acute ischemic stroke, but can cause vascular damage leading to edema …

Tissue plasminogen activator (tPA) administered within 4.5 h of symptom onset restores
cerebral blood flow (CBF) and promotes neurological recovery of stroke patients. However …

Background and Purpose—Stroke remains a common medical problem with importance
attributable to the demographic changes in industrialized societies. Summary of Review …

What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator
(tPA) is the only available evidence‐based treatment for acute ischaemic stroke; however, its …

Reperfusion therapy with tissue plasminogen activator (tPA) is a rational therapy for acute
ischemic stroke. Properly titrated use of tPA improves clinical outcomes. However, there is …

This review focuses on the mechanisms and emerging concepts of stroke and therapeutic
strategies for attenuating hemorrhagic transformation (HT) after tissue plasminogen activator …